|
Gene: RNF123 |
Gene summary for RNF123 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RNF123 | Gene ID | 63891 |
Gene name | ring finger protein 123 | |
Gene Alias | FP1477 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q5XPI4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
63891 | RNF123 | HCC1_Meng | Human | Liver | HCC | 6.11e-34 | 2.84e-02 | 0.0246 |
63891 | RNF123 | HCC2 | Human | Liver | HCC | 6.64e-05 | 2.56e+00 | 0.5341 |
63891 | RNF123 | S015 | Human | Liver | HCC | 2.53e-05 | 4.24e-01 | 0.2375 |
63891 | RNF123 | S028 | Human | Liver | HCC | 2.86e-11 | 5.55e-01 | 0.2503 |
63891 | RNF123 | S029 | Human | Liver | HCC | 9.83e-08 | 5.48e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RNF123 | SNV | Missense_Mutation | novel | c.3114N>A | p.Asn1038Lys | p.N1038K | Q5XPI4 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RNF123 | SNV | Missense_Mutation | c.3520N>A | p.Val1174Met | p.V1174M | Q5XPI4 | protein_coding | deleterious(0.03) | probably_damaging(0.991) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
RNF123 | SNV | Missense_Mutation | novel | c.719N>G | p.Ser240Cys | p.S240C | Q5XPI4 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RNF123 | SNV | Missense_Mutation | novel | c.1879N>T | p.Val627Leu | p.V627L | Q5XPI4 | protein_coding | tolerated(0.98) | benign(0) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
RNF123 | deletion | Frame_Shift_Del | c.586delG | p.Asp196ThrfsTer3 | p.D196Tfs*3 | Q5XPI4 | protein_coding | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |||
RNF123 | deletion | Frame_Shift_Del | novel | c.1024delN | p.Leu342CysfsTer40 | p.L342Cfs*40 | Q5XPI4 | protein_coding | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
RNF123 | SNV | Missense_Mutation | rs561463017 | c.916C>T | p.Arg306Trp | p.R306W | Q5XPI4 | protein_coding | deleterious(0.01) | benign(0.109) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RNF123 | SNV | Missense_Mutation | novel | c.1295C>A | p.Ser432Tyr | p.S432Y | Q5XPI4 | protein_coding | tolerated(0.11) | possibly_damaging(0.823) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RNF123 | SNV | Missense_Mutation | c.2833N>C | p.Glu945Gln | p.E945Q | Q5XPI4 | protein_coding | deleterious(0.02) | benign(0.193) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
RNF123 | SNV | Missense_Mutation | novel | c.2566N>T | p.Gly856Trp | p.G856W | Q5XPI4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |